Revance Therapeutics Stock News

Revance Therapeutics (NASDAQ:RVNC) is scheduled to announce Q4 earnings results on Monday, February 28th, after market close.The consensus EPS Estimate is -$1.03 (+16.9% Y/Y) and…

Revance Therapeutics, Inc. (RVNC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Revance Therapeutics, Inc. (RVNC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NEW YORK, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-09585, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Revance securities between November 25, 2019 and October 11, 2021, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

SAN DIEGO, Feb. 06, 2022 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Revance Therapeutics, Inc. (NASDAQ: RVNC) securities between November 25, 2019 and October 11, 2021, inclusive (Class Period) have until this upcoming Tuesday, February 8, 2022, to seek appointment as lead plaintiff in Aramic LLC v. Revance Therapeutics, Inc. , No. 21-cv-09585 (N.D. Cal.). Commenced on December 10, 2021, the Revance Therapeutics class action lawsuit charges Revance Therapeutics along with certain of its top executives with violations of the Securities Exchange Act of 1934.

SAN DIEGO--(BUSINESS WIRE)-- #RVNCstock--The suit alleges defendants issued false statements re: Revance Therapeutics business & prospects, resulting in its stock trading at inflated prices.

Kessler Topaz Meltzer & Check, LLP Reminds Revance Therapeutics, Inc. (RVNC) Investors of Filing Deadline in Class Action Lawsuit

SAN FRANCISCO, Feb. 05, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Revance Therapeutics, Inc. (NASDAQ: RVNC) investors to with significant losses to submit your losses now .

/PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed

NEW YORK, Feb. 02, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Revance Therapeutics, Inc. (NASDAQ: RVNC) between November 25, 2019 and October 11, 2021, inclusive (the Class Period), of the important February 8, 2022 lead plaintiff deadline .

Baron Funds, an asset management firm, published its Baron Discovery Fund fourth quarter 2021 investor letter a copy of which can be downloaded here.

NEW ORLEANS, Jan. 19, 2022 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Berkeley Lights, Inc. (BLI) Class Period: 7/17/2020 - 9/14/2021 Lead Plaintiff Motion Deadline: February 7, 2022 SECURITIES FRAUD To learn more, visit https://claimsfiler.com/cases/nasdaq-bli/ Cloopen Group Holding Limited (RAAS) Class Period: 2/9/2021 - 5/10/2021; American Depositary Shares issued either in or after the February 2021 Initial Public Offering Lead Plaintiff Motion Deadline: February 8, 2022 SECURITIES FRAUD, MISLEADING PROSPECTUS Full story available on Benzinga.com